Univariable model | Gradient of risk (standardized Hazard ratio by 1 SD) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Predictors | n (%) events | N | Hazard ratio (95% CI) | p-value | PH p value | SD | Hazard ratio (95% CI) | Effect ordering | |
Total cholesterol (mmol/L) | Risk by 1 unit increase | 97 (13.1%) | 739 | 1.34 (1.11–1.61) | 0.0022 | 0.70 | 1.04 | 1.35 (1.12–1.64) | 5 |
Hyperlipidemia | No hyperlipidemia | 56 (11.8%) | 739 | ||||||
Hyperlipidemia | 41 (15.6%) | 1.34 (0.89–2.00) | 0.16 | 0.44 | 0.48 | 1.15 (0.95–1.39) | |||
HDL cholesterol (mmol/L) | Risk by 0.2 units decrease | 91 (12.8%) | 710 | 1.45 (1.24–1.69) | < .0001 | 0.0013 Neg | 0.34 | 1.89 (1.45–2.45) | 1 |
Systolic BP (mmHg) | Risk by 1 unit increase | 97 (13.2%) | 736 | 1.02 (1.01–1.03) | 0.0006 | 0.78 | 17.25 | 1.36 (1.14–1.63) | 4 |
Diastolic BP (mmHg) | Risk by 1 unit increase | 97 (13.2%) | 736 | 1.03 (1.01–1.05) | 0.0024 | 0.51 | 10.61 | 1.34 (1.11–1.63) | 6 |
Hypertension | No hypertension | 41 (9.2%) | 739 | ||||||
Hypertension | 56 (19.2%) | 2.30 (1.53–3.44) | < .0001 | 0.54 | 0.49 | 1.50 (1.23–1.83) | 2 | ||
Smoking | Non-smoker | 60 (11.7%) | 739 | ||||||
Smoker | 37 (16.2%) | 1.54 (1.02–2.32) | 0.040 | 0.062 | 0.46 | 1.22 (1.01–1.47) | 13 | ||
BMI (kg/m2) | Risk by 1 unit increase | 97 (13.1%) | 739 | 1.07 (1.01–1.13) | 0.018 | 0.21 | 3.42 | 1.25 (1.04–1.50) | 11 |
Fasting plasma glucose (mmol/L) | Risk by 1 unit increase | 97 (13.2%) | 736 | 1.17 (1.05–1.30) | 0.0040 | 0.43 | 1.26 | 1.22 (1.06–1.39) | 12 |
Physical activity | Moderate or regular exercise | 77 (12.3%) | 739 | ||||||
Sedentary leisure time | 20 (17.9%) | 1.50 (0.92–2.45) | 0.11 | 0.55 | 0.36 | 1.16 (0.97–1.38) | |||
High-sensitivity C-reactive Protein (mg/L) | Risk by 5 unit increase | 97 (13.1%) | 739 | 1.13 (0.91–1.40) | 0.25 | 0.0025 Neg | 3.60 | 1.09 (0.94–1.28) | |
hsCRP > 1 mg/L | ≤ 1 mg/L | 27 (9.3%) | 739 | ||||||
> 1 mg/L | 70 (15.6%) | 1.82 (1.17–2.84) | 0.0080 | 0.0069 Neg | 0.49 | 1.34 (1.08–1.67) | 7 | ||
hsCRP > 2 mg/L | ≤ 2 mg/L | 64 (12.8%) | 739 | ||||||
> 2 mg/L | 33 (13.8%) | 1.15 (0.76–1.75) | 0.52 | 0.0007 Neg | 0.47 | 1.07 (0.88–1.30) | |||
hsCRP > 3 mg/L | ≤ 3 mg/L | 80 (13.2%) | 739 | ||||||
> 3 mg/L | 17 (12.6%) | 1.02 (0.61–1.73) | 0.93 | 0.0031 Neg | 0.39 | 1.01 (0.82–1.23) | |||
NT-proBNP (pg/mL) | Risk by 20 unit increase | 97 (13.1%) | 739 | 1.02 (0.92–1.12) | 0.73 | 0.20 | 40.72 | 1.04 (0.85–1.26) | |
NT-proBNP > 50 pg/mL | ≤ 50 pg/mL | 82 (13.5%) | 739 | ||||||
> 50 pg/mL | 15 (11.4%) | 1.13 (0.65–1.96) | 0.66 | 0.77 | 0.38 | 1.05 (0.85–1.30) | |||
NT-proBNP > 100 pg/mL | ≤ 100 pg/mL | 92 (13.2%) | 739 | ||||||
> 100 pg/mL | 5 (12.2%) | 1.00 (0.41–2.47) | 0.99 | 0.39 | 0.23 | 1.00 (0.81–1.23) | |||
High-sensitivity Troponin-T (ng/L) | Risk by 1 unit increase | 97 (13.1%) | 739 | 1.05 (1.01–1.10) | 0.028 | 0.23 | 3.30 | 1.17 (1.02–1.35) | 15 |
High-sensitivity Troponin-T > 3 (ng/L) | ≤ 3 | 21 (9.1%) | 739 | ||||||
> 3 | 76 (15.0%) | 1.76 (1.09–2.86) | 0.021 | 0.85 | 0.46 | 1.30 (1.04–1.63) | 9 | ||
High-sensitivity Troponin-T > 5 (ng/L) | ≤ 5 | 57 (12.0%) | 739 | ||||||
> 5 | 40 (15.1%) | 1.31 (0.87–1.96) | 0.19 | 0.34 | 0.48 | 1.14 (0.94–1.38) | |||
High-sensitivity Troponin-T > 10 (ng/L) | ≤ 10 | 87 (12.4%) | 739 | ||||||
> 10 | 10 (25.6%) | 2.33 (1.21–4.48) | 0.011 | 0.39 | 0.22 | 1.21 (1.04–1.40) | 14 | ||
High-sensitivity Troponin-T ≤ 3/3–10/ > 10 (ng/L) | ≤ 3 | 21 (9.1%) | 739 | ||||||
> 3–10 | 66 (14.1%) | 1.65 (1.01–2.69) | 0.047 | 0.71 | 0.48 | 1.27 (1.00–1.61) | 10 | ||
> 10 | 10 (25.6%) | 3.31 (1.56–7.04) | 0.0018 | 0.59 | 0.22 | 1.30 (1.10–1.54) | 8 | ||
IL-6 | Risk by 5 unit increase | 95 (12.9%) | 736 | 1.17 (1.00–1.36) | 0.044 | 0.71 | 3.90 | 1.13 (1.00–1.27) | 16 |
IL-6 > 8 | ≤ 8 | 92 (12.8%) | 736 | ||||||
> 8 | 3 (15.8%) | 1.46 (0.46–4.61) | 0.52 | 0.034 Neg | 0.16 | 1.06 (0.88–1.27) | |||
Number of risk biomarkers with elevated levels (hsCRP > 1/NT-proBNP > 100/hsTroponin-T > 10/IL6 > 8) | Risk by 1 unit increase | 97 (13.1%) | 739 | 1.64 (1.21–2.21) | 0.0014 | 0.0016 Neg | 0.63 | 1.37 (1.13–1.65) | 3 |